Immunocore Q3KIMMTRAKrevenues rise ~10%, TEBE-AMresultsexpected Q2'27
Immunocore reported Q3 net product revenues of $102.2 million, driven by year-over-year growth normalized for inventory shifts. The company also announced TEBE-AM trial target enrollment completion, with top-line survival data expected in Q2 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed